neuraxon


Also found in: Dictionary.

neu·rax·on

, neuraxone (nū-rak'son, -sōn),
Obsolete term for axon.
[neur- + G. axōn, axis]

neuraxon

, neuraxone (nū-răks′ōn)
A term formerly used for an axon.

neuraxon

axon.
References in periodicals archive ?
NeurAxon is designing and developing pain medicines targeting neuronal nitric oxide synthase (nNOS).
Ferrer commercial director Paul Simpson says the company feels that cognition will emerge as a significant segment of the vitamin and nutrition category and high-quality products like NeurAxon will come to dominate the market.
One study has shown that NeurAxon can improve memory function in adults in as little as a month of daily use.
Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 clinical development for the treatment of acute migraine.
NeurAxon to Present at Windhover's Therapeutic Area Partnerships Conference on November 3 -
We are grateful for the continuing support of our existing investors and welcome CTI and the Ontario Capital Growth Corporation as the two most recent additions to the NeurAxon team.
These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.
The NeurAxon presentation will be delivered on Thursday, August 5, 2010 at 11:15am Eastern Time at the Sheraton New York Hotel & Towers.
The NeurAxon presentation will be delivered on Wednesday, June 9, 2010 at 3:00pm Eastern Time at the New York Palace Hotel.
NeurAxon is focused on the discovery and development of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.
Andrews PhD, President and Head of R&D of NeurAxon and Principal Investigator under the grant.
NeurAxon will use the net proceeds from the financing to support ongoing research and development efforts for its internally generated pipeline of selective inhibitors of nNOS, an enzyme involved in modulating pain and central nervous system neuronal sensitization.